Perspectives on the 340B Drug Discount Program

July 3, 2018

Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.

Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.

Gamble says that at first, everyone was very excited when this rule came out. However, he suggested that cuts to drug payments have benefitted hospitals in the 340B program.